NO782128L - Fremgangsmaate for fremstilling av fysiologisk aktive isonikotinsyrederivater - Google Patents

Fremgangsmaate for fremstilling av fysiologisk aktive isonikotinsyrederivater

Info

Publication number: NO782128L
Authority: NO; Norway
Prior art keywords: group; compound; general formula; acid; hydrogen
Prior art date: 1977-06-20

Application number

NO782128A

Other languages

English (en)

Norwegian (no)

Inventor

Povl Krogsgaard-Larsen

Erik Falch

Original Assignee

Krogsgaard Larsen Povl

Erik Falch

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-06-20

Filing date

1978-06-19

Publication date

1978-12-21

1978-06-19 Application filed by Krogsgaard Larsen Povl, Erik Falch filed Critical Krogsgaard Larsen Povl

1978-12-21 Publication of NO782128L publication Critical patent/NO782128L/no

Links

238000002360 preparation method Methods 0.000 title claims description 23
239000002253 acid Substances 0.000 title claims description 14
238000000034 method Methods 0.000 title claims description 9
150000001875 compounds Chemical class 0.000 claims description 80
150000003839 salts Chemical class 0.000 claims description 37
229910052739 hydrogen Inorganic materials 0.000 claims description 32
239000001257 hydrogen Substances 0.000 claims description 31
229940125890 compound Ia Drugs 0.000 claims description 22
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 19
-1 formic acid ester Chemical class 0.000 claims description 19
125000000217 alkyl group Chemical group 0.000 claims description 17
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 16
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
229910052736 halogen Inorganic materials 0.000 claims description 13
150000002367 halogens Chemical class 0.000 claims description 13
150000002431 hydrogen Chemical class 0.000 claims description 12
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 12
125000003545 alkoxy group Chemical group 0.000 claims description 11
125000003884 phenylalkyl group Chemical group 0.000 claims description 10
238000006243 chemical reaction Methods 0.000 claims description 9
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
235000019253 formic acid Nutrition 0.000 claims description 6
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 5
125000003710 aryl alkyl group Chemical group 0.000 claims description 5
KRVDMABBKYMBHG-UHFFFAOYSA-N Isoguvacine Chemical compound OC(=O)C1=CCNCC1 KRVDMABBKYMBHG-UHFFFAOYSA-N 0.000 claims description 4
125000003118 aryl group Chemical group 0.000 claims description 4
230000007062 hydrolysis Effects 0.000 claims description 4
238000006460 hydrolysis reaction Methods 0.000 claims description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
125000003107 substituted aryl group Chemical group 0.000 claims description 4
239000011230 binding agent Substances 0.000 claims description 3
238000007327 hydrogenolysis reaction Methods 0.000 claims description 3
JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 claims description 3
YVIHCEXQAJNSKX-UHFFFAOYSA-N 2,2-dimethylpropanoyloxymethyl 1,2,3,6-tetrahydropyridine-4-carboxylate Chemical compound CC(C)(C)C(=O)OCOC(=O)C1=CCNCC1 YVIHCEXQAJNSKX-UHFFFAOYSA-N 0.000 claims description 2
150000001242 acetic acid derivatives Chemical class 0.000 claims description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
125000006239 protecting group Chemical group 0.000 claims description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims 3
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 2
FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 claims 2
150000008064 anhydrides Chemical class 0.000 claims 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
239000002516 radical scavenger Substances 0.000 claims 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 46
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 23
229960003692 gamma aminobutyric acid Drugs 0.000 description 23
239000000243 solution Substances 0.000 description 19
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical compound NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 description 15
238000002844 melting Methods 0.000 description 14
230000008018 melting Effects 0.000 description 14
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 11
230000000694 effects Effects 0.000 description 11
239000000203 mixture Substances 0.000 description 11
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
210000004556 brain Anatomy 0.000 description 9
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
238000010992 reflux Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 6
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
PFVFXDVOCHMQDU-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridine-4-carboxylic acid Chemical compound OC(=O)C1CCNC=C1 PFVFXDVOCHMQDU-UHFFFAOYSA-N 0.000 description 5
238000000354 decomposition reaction Methods 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
230000028327 secretion Effects 0.000 description 5
102000003946 Prolactin Human genes 0.000 description 4
108010057464 Prolactin Proteins 0.000 description 4
229960000583 acetic acid Drugs 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
239000002585 base Substances 0.000 description 4
230000008499 blood brain barrier function Effects 0.000 description 4
210000001218 blood-brain barrier Anatomy 0.000 description 4
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
229910000041 hydrogen chloride Inorganic materials 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
230000007257 malfunction Effects 0.000 description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
229940097325 prolactin Drugs 0.000 description 4
238000001953 recrystallisation Methods 0.000 description 4
239000007787 solid Substances 0.000 description 4
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
208000023105 Huntington disease Diseases 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
235000019439 ethyl acetate Nutrition 0.000 description 3
229910000042 hydrogen bromide Inorganic materials 0.000 description 3
238000002329 infrared spectrum Methods 0.000 description 3
239000003921 oil Substances 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
150000002990 phenothiazines Chemical class 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000004809 thin layer chromatography Methods 0.000 description 3
RLJKFAMYSYWMND-GRTNUQQKSA-M (6r)-6-[(5s)-6,6-dimethyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-6-ium-5-yl]-6h-furo[3,4-g][1,3]benzodioxol-8-one;chloride Chemical compound [Cl-].O([C@H]1[C@@H]2C3=CC=4OCOC=4C=C3CC[N+]2(C)C)C(=O)C2=C1C=CC1=C2OCO1 RLJKFAMYSYWMND-GRTNUQQKSA-M 0.000 description 2
WKYGMSYBNGFBEX-UHFFFAOYSA-N 1,2,3,6-tetrahydropyridine-4-carboxylic acid;hydrobromide Chemical compound Br.OC(=O)C1=CCNCC1 WKYGMSYBNGFBEX-UHFFFAOYSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
FTCQLFBQQZDCQA-UHFFFAOYSA-N 1-trityl-3,6-dihydro-2h-pyridine-4-carboxylic acid Chemical compound C1CC(C(=O)O)=CCN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 FTCQLFBQQZDCQA-UHFFFAOYSA-N 0.000 description 2
MZWLADOOFUTXPI-UHFFFAOYSA-N 2,2-dimethylpropanoyloxymethyl 1,2,3,6-tetrahydropyridine-4-carboxylate;hydrobromide Chemical compound Br.CC(C)(C)C(=O)OCOC(=O)C1=CCNCC1 MZWLADOOFUTXPI-UHFFFAOYSA-N 0.000 description 2
ICJWWLYKZUYLCT-UHFFFAOYSA-N 3-hydroxypiperidine-4-carboxylic acid;hydrochloride Chemical compound Cl.OC1CNCCC1C(O)=O ICJWWLYKZUYLCT-UHFFFAOYSA-N 0.000 description 2
241000134914 Amanita muscaria Species 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
102000005915 GABA Receptors Human genes 0.000 description 2
108010005551 GABA Receptors Proteins 0.000 description 2
229940121909 GABA receptor agonist Drugs 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
206010062767 Hypophysitis Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
208000027089 Parkinsonian disease Diseases 0.000 description 2
206010034010 Parkinsonism Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000012230 colorless oil Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
239000003814 drug Substances 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
230000006870 function Effects 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
230000035873 hypermotility Effects 0.000 description 2
239000000960 hypophysis hormone Substances 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical class OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
150000004702 methyl esters Chemical class 0.000 description 2
229960005181 morphine Drugs 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
210000003635 pituitary gland Anatomy 0.000 description 2
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
239000000047 product Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
201000000980 schizophrenia Diseases 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
ISHLCKAQWKBMAU-UHFFFAOYSA-N tert-butyl n-diazocarbamate Chemical compound CC(C)(C)OC(=O)N=[N+]=[N-] ISHLCKAQWKBMAU-UHFFFAOYSA-N 0.000 description 2
238000012360 testing method Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000024883 vasodilation Effects 0.000 description 2
YWJLYDGNYAZLTN-UHFFFAOYSA-N (2-phenylacetyl)oxymethyl 1,2,3,6-tetrahydropyridine-4-carboxylate Chemical compound C=1CNCCC=1C(=O)OCOC(=O)CC1=CC=CC=C1 YWJLYDGNYAZLTN-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
SMNWDTHJSPTXJT-UHFFFAOYSA-N 1-(4-chlorophenoxy)carbonyl-3,6-dihydro-2h-pyridine-4-carboxylic acid Chemical compound C1CC(C(=O)O)=CCN1C(=O)OC1=CC=C(Cl)C=C1 SMNWDTHJSPTXJT-UHFFFAOYSA-N 0.000 description 1
GMCOILLDURLTQK-UHFFFAOYSA-N 1-(4-methoxyphenoxy)carbonyl-3,6-dihydro-2h-pyridine-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1OC(=O)N1CC=C(C(O)=O)CC1 GMCOILLDURLTQK-UHFFFAOYSA-N 0.000 description 1
ULIZLOYJESBEQP-UHFFFAOYSA-N 1-(4-methylphenoxy)carbonyl-3,6-dihydro-2h-pyridine-4-carboxylic acid Chemical compound C1=CC(C)=CC=C1OC(=O)N1CC=C(C(O)=O)CC1 ULIZLOYJESBEQP-UHFFFAOYSA-N 0.000 description 1
VXFNKGMGJZDHCD-UHFFFAOYSA-N 1-acetyl-3,6-dihydro-2h-pyridine-4-carboxylic acid Chemical compound CC(=O)N1CCC(C(O)=O)=CC1 VXFNKGMGJZDHCD-UHFFFAOYSA-N 0.000 description 1
MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
BNRJEFPEEYASCL-UHFFFAOYSA-N 1-butoxycarbonyl-3,6-dihydro-2h-pyridine-4-carboxylic acid Chemical compound CCCCOC(=O)N1CCC(C(O)=O)=CC1 BNRJEFPEEYASCL-UHFFFAOYSA-N 0.000 description 1
MHIKJQMGPHGMEZ-UHFFFAOYSA-N 1-ethoxycarbonyl-3,6-dihydro-2h-pyridine-4-carboxylic acid Chemical compound CCOC(=O)N1CCC(C(O)=O)=CC1 MHIKJQMGPHGMEZ-UHFFFAOYSA-N 0.000 description 1
AYQAKNRNHIUKIY-UHFFFAOYSA-N 1-methyl-3,6-dihydro-2h-pyridine-4-carboxylic acid;hydrochloride Chemical compound [Cl-].C[NH+]1CCC(C(O)=O)=CC1 AYQAKNRNHIUKIY-UHFFFAOYSA-N 0.000 description 1
HGIVSKXVQGXEAV-UHFFFAOYSA-N 1-phenoxycarbonyl-3,6-dihydro-2h-pyridine-4-carboxylic acid Chemical compound C1CC(C(=O)O)=CCN1C(=O)OC1=CC=CC=C1 HGIVSKXVQGXEAV-UHFFFAOYSA-N 0.000 description 1
FRWCNDVEBMIVDG-UHFFFAOYSA-N 1-phenylmethoxycarbonyl-3,6-dihydro-2h-pyridine-4-carboxylic acid Chemical compound C1CC(C(=O)O)=CCN1C(=O)OCC1=CC=CC=C1 FRWCNDVEBMIVDG-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
OCDFFPRVRQLOAE-UHFFFAOYSA-N 2-acetyloxypropan-2-yl 1,2,3,6-tetrahydropyridine-4-carboxylate Chemical compound CC(=O)OC(C)(C)OC(=O)C1=CCNCC1 OCDFFPRVRQLOAE-UHFFFAOYSA-N 0.000 description 1
JEJFXQFDECUFAX-UHFFFAOYSA-N 2-ethylbutanoyloxymethyl 1,2,3,6-tetrahydropyridine-4-carboxylate Chemical compound CCC(CC)C(=O)OCOC(=O)C1=CCNCC1 JEJFXQFDECUFAX-UHFFFAOYSA-N 0.000 description 1
NJPPWBLCPTZCOL-UHFFFAOYSA-N 2-methylpropanoyloxymethyl 1,2,3,6-tetrahydropyridine-4-carboxylate Chemical compound CC(C)C(=O)OCOC(=O)C1=CCNCC1 NJPPWBLCPTZCOL-UHFFFAOYSA-N 0.000 description 1
239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 description 1
MVQROXPEZULQEP-UHFFFAOYSA-N 4-o-ethyl 1-o-methyl 3-hydroxypiperidine-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC)CC1O MVQROXPEZULQEP-UHFFFAOYSA-N 0.000 description 1
PTKLDHADMDDGDN-UHFFFAOYSA-N 4-o-ethyl 1-o-methyl 3-oxopiperidine-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC)CC1=O PTKLDHADMDDGDN-UHFFFAOYSA-N 0.000 description 1
PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
235000006491 Acacia senegal Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
206010047141 Vasodilatation Diseases 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
MHLMRBVCMNDOCW-UHFFFAOYSA-N acetic acid;butan-1-ol;hydrate Chemical compound O.CC(O)=O.CCCCO MHLMRBVCMNDOCW-UHFFFAOYSA-N 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
UNQJZCVCDPKMAK-UHFFFAOYSA-N acetyloxymethyl 1,2,3,6-tetrahydropyridine-4-carboxylate Chemical compound CC(=O)OCOC(=O)C1=CCNCC1 UNQJZCVCDPKMAK-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
JFWIRJZMFJWEKQ-UHFFFAOYSA-N benzoyloxymethyl 1,2,3,6-tetrahydropyridine-4-carboxylate Chemical compound C=1CNCCC=1C(=O)OCOC(=O)C1=CC=CC=C1 JFWIRJZMFJWEKQ-UHFFFAOYSA-N 0.000 description 1
HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 1
238000009835 boiling Methods 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
KTTYCCHHKLNNMY-UHFFFAOYSA-N butanoyloxymethyl 1,2,3,6-tetrahydropyridine-4-carboxylate Chemical compound CCCC(=O)OCOC(=O)C1=CCNCC1 KTTYCCHHKLNNMY-UHFFFAOYSA-N 0.000 description 1
PDQOMVCEIFSXDN-UHFFFAOYSA-N butyl 1,2,3,6-tetrahydropyridine-4-carboxylate Chemical compound CCCCOC(=O)C1=CCNCC1 PDQOMVCEIFSXDN-UHFFFAOYSA-N 0.000 description 1
IYVYJDZFDIOPRN-UHFFFAOYSA-N butyl 1,2,3,6-tetrahydropyridine-4-carboxylate;hydrobromide Chemical compound Br.CCCCOC(=O)C1=CCNCC1 IYVYJDZFDIOPRN-UHFFFAOYSA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
XKMYLRYRMPTNPE-UHFFFAOYSA-N diethyl 3,6-dihydro-2h-pyridine-1,4-dicarboxylate Chemical compound CCOC(=O)N1CCC(C(=O)OCC)=CC1 XKMYLRYRMPTNPE-UHFFFAOYSA-N 0.000 description 1
GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
238000004821 distillation Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
230000003400 hallucinatory effect Effects 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
125000001183 hydrocarbyl group Chemical group 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
210000001153 interneuron Anatomy 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
229960003350 isoniazid Drugs 0.000 description 1
QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000000155 melt Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
YJBXHMHSOCHRLV-UHFFFAOYSA-N methyl 1,2,3,6-tetrahydropyridine-4-carboxylate Chemical compound COC(=O)C1=CCNCC1 YJBXHMHSOCHRLV-UHFFFAOYSA-N 0.000 description 1
BJLGIRWBYKEMDX-UHFFFAOYSA-N methyl 1,2,3,6-tetrahydropyridine-4-carboxylate;hydrobromide Chemical compound Br.COC(=O)C1=CCNCC1 BJLGIRWBYKEMDX-UHFFFAOYSA-N 0.000 description 1
YTSAAQMJVBJTJS-UHFFFAOYSA-N methyl 1,2,3,6-tetrahydropyridine-4-carboxylate;hydrochloride Chemical compound Cl.COC(=O)C1=CCNCC1 YTSAAQMJVBJTJS-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000007659 motor function Effects 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
LKVYWSOUXPAASC-UHFFFAOYSA-N propan-2-yl 1,2,3,6-tetrahydropyridine-4-carboxylate Chemical compound CC(C)OC(=O)C1=CCNCC1 LKVYWSOUXPAASC-UHFFFAOYSA-N 0.000 description 1
QFPHZWKUUXPCHL-UHFFFAOYSA-N propanoyloxymethyl 1,2,3,6-tetrahydropyridine-4-carboxylate Chemical compound CCC(=O)OCOC(=O)C1=CCNCC1 QFPHZWKUUXPCHL-UHFFFAOYSA-N 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
PBMDISAJJZPQKQ-UHFFFAOYSA-N propyl 1,2,3,6-tetrahydropyridine-4-carboxylate Chemical compound CCCOC(=O)C1=CCNCC1 PBMDISAJJZPQKQ-UHFFFAOYSA-N 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
235000012976 tarts Nutrition 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
235000015149 toffees Nutrition 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyridine Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)

NO782128A 1977-06-20 1978-06-19 Fremgangsmaate for fremstilling av fysiologisk aktive isonikotinsyrederivater NO782128L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB2574077		1977-06-20

Publications (1)

Publication Number	Publication Date
NO782128L true NO782128L (no)	1978-12-21

Family

ID=10232513

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO782128A NO782128L (no)	1977-06-20	1978-06-19	Fremgangsmaate for fremstilling av fysiologisk aktive isonikotinsyrederivater
NO782127A NO152049C (no)	1977-06-20	1978-06-19	Analogifremgangsmaate for fremstilling av den farmasoeytisk anvendelige forbindelse 4,5,6,7-tetrahydroisoksazolo (5,4-c)pyridin-3-ol
NO792839A NO792839L (no)	1977-06-20	1979-09-03	Mellomprodukt for anvendelse ved fremstilling av fysiologisk aktive isonikotinsyrederivater

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NO782127A NO152049C (no)	1977-06-20	1978-06-19	Analogifremgangsmaate for fremstilling av den farmasoeytisk anvendelige forbindelse 4,5,6,7-tetrahydroisoksazolo (5,4-c)pyridin-3-ol
NO792839A NO792839L (no)	1977-06-20	1979-09-03	Mellomprodukt for anvendelse ved fremstilling av fysiologisk aktive isonikotinsyrederivater

Country Status (14)

Country	Link
US (2)	US4278676A (de)
EP (4)	EP0028017A1 (de)
JP (2)	JPS5436290A (de)
AT (1)	AT368505B (de)
AU (2)	AU3724478A (de)
CA (1)	CA1107736A (de)
DK (2)	DK270378A (de)
ES (2)	ES470912A1 (de)
FI (2)	FI781955A7 (de)
IE (1)	IE47200B1 (de)
IT (2)	IT7868449A0 (de)
NO (3)	NO782128L (de)
NZ (1)	NZ187615A (de)
ZA (2)	ZA783492B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3145473A1 (de) *	1980-11-27	1982-08-26	Kefalas A/S, Koebenhavn-Valby	2-substituierte 4,5,6,7-tetrahydroisoxazolo (5,4-c) pyridin-3-on-verbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3145474A1 (de) *	1980-11-27	1982-09-02	Kefalas A/S, Koebenhavn-Valby	3-substituierte 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridinverbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
EP0083378A1 (de) *	1981-12-22	1983-07-13	Chugai Seiyaku Kabushiki Kaisha	Tetrahydronicotinsäureamide, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
GB8314391D0 (en) *	1983-05-24	1983-06-29	Kefalas As	Heterocyclic compounds
IT1228426B (it) *	1987-07-20	1991-06-17	Ausimont Spa	Perossiacidi eterociclici
US4859666A (en) *	1988-07-06	1989-08-22	Bristol-Myers Company	THAZ derivatives for enhancement of cerebral function
CN1043051C (zh) *	1994-07-22	1999-04-21	国际壳牌研究有限公司	制备氢化石蜡的方法
BRPI0410857A (pt)	2003-06-25	2006-07-04	Lundbeck & Co As H	método para o tratamento de depressão, uso de gaboxadol, e, composição farmacêutica
US20050234093A1 (en) *	2003-06-25	2005-10-20	H. Lundbeck A/S	Treatment of depression and other affective disorders
AR045540A1 (es) *	2003-09-05	2005-11-02	Lundbeck & Co As H	Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
PL1691811T3 (pl)	2003-12-11	2014-12-31	Sunovion Pharmaceuticals Inc	Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
US20050137222A1 (en) *	2003-12-18	2005-06-23	H. Lundbeck A/S	Treatment of insomnia in human patients
US20050215521A1 (en) *	2003-12-22	2005-09-29	Karim Lalji	Modafinil combination therapy for improving sleep quality
EP1696959A2 (de) *	2003-12-24	2006-09-06	Sepracor, Inc.	Melatonin-kombinationstherapie zur verbesserung der schlafqualität
GB0402118D0 (en) *	2004-01-30	2004-03-03	Merck Sharp & Dohme	Polymorphic forms of a GABAA agonist
DK1742624T3 (da) *	2004-02-18	2010-03-08	Sepracor Inc	Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet
GB0417558D0 (en) *	2004-08-06	2004-09-08	Merck Sharp & Dohme	Novel combination therapy
EP1848420A4 (de)	2005-01-28	2008-01-23	Merck & Co Inc	Polymorphe formen eines gabaa-agonisten
US20080262029A1 (en) *	2005-04-29	2008-10-23	H. Lundbeck A/S	Acid and Base Salt Forms of Gaboxadol
EP2258358A3 (de)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenese mit Acetylcholinesterasehemmer
EP2275095A3 (de)	2005-08-26	2011-08-17	Braincells, Inc.	Neurogenese durch modulation des Muscarinrezeptors
EP1940389A2 (de)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation von neurogenese durch pde-hemmung
AU2006308889A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	GABA receptor mediated modulation of neurogenesis
US20070203216A1 (en) *	2006-02-14	2007-08-30	Bjarke Ebert	Method of treating inflammatory diseases
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
JP2009536667A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	５ｈｔ受容体介在性の神経新生
EP2382975A3 (de)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenese mittels Angiotensin-Modulation
AU2007292848A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100193652A1 (en) *	2009-02-02	2010-08-05	William Stajos	Wall Display System And Method Of Providing The Same
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
US8784835B2 (en) *	2012-07-02	2014-07-22	Trent Austin	Method for producing muscimol and/or reducing ibotenic acid from amanita tissue
CN104974175A (zh) *	2014-04-11	2015-10-14	天津药物研究院	一种氨甲基羟异恶唑类似物的制备方法
RS62007B1 (sr)	2014-06-06	2021-07-30	Ovid Therapeutics Inc	Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma
LT3274331T (lt)	2015-03-24	2020-04-10	H. Lundbeck A/S	4,5,6,7-tetrahidroizozaksolo[5,4-c]piridin-3-olio gamybos būdas
US9682069B2 (en)	2015-07-17	2017-06-20	Ovid Therapeutics Inc	Methods of treating Dravet syndrome
EP4541420A3 (de)	2015-07-17	2025-06-25	Ovid Therapeutics Inc.	Verfahren zur behandlung von entwicklungsstörungen mit gaboxadol
US9399034B1 (en)	2015-08-11	2016-07-26	Ovid Therapeutics Inc	Methods of sedation during critical care treatment
EP3481387A4 (de)	2016-08-11	2020-04-08	Ovid Therapeutics Inc	Verfahren und zusammensetzungen zur behandlung von epileptischen erkrankungen
US10071083B2 (en)	2017-02-03	2018-09-11	Ovid Therapeutics Inc	Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en)	2017-05-24	2018-11-29	Ovid Therapeutics Inc.	Treatment of depressive disorders
JP2020529440A (ja)	2017-08-04	2020-10-08	オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄＴｈｅｒａｐｅｕｔｉｃｓＩｎｃ．	糖尿病および関連する状態の処置におけるガボキサドールの使用
WO2020061410A1 (en)	2018-09-20	2020-03-26	Ovid Therapeutics Inc.	Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
JP2022514194A (ja)	2018-11-21	2022-02-10	セルテゴセラピューティクスインコーポレイテッド	自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
WO2020131856A1 (en)	2018-12-17	2020-06-25	Ovid Therapeutics Inc.	Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
MX2022014599A (es)	2020-05-20	2022-12-16	Certego Therapeutics Inc	Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
CN114292224B (zh) *	2022-03-07	2022-05-20	中国农业科学院农产品加工研究所	一种大麻二酚-2-（n-乙酰基）哌啶酸酯及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2784190A (en) *	1952-03-28	1957-03-05	Upjohn Co	Alkyl piperidinepropionates
CA762455A (en) *	1962-03-22	1967-07-04	Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung	Pyrido-pyrimidines
US3381016A (en) *	1966-03-04	1968-04-30	Upjohn Co	Isoxazolo[5, 4-b]pyridine derivatives and a method for their preparation
DE2221770A1 (de) *	1972-05-04	1973-11-15	Bayer Ag	Verfahren zur herstellung von tetrahydropyridinen
DK62791A (da) *	1991-04-09	1992-11-09	Tulip Int As	Fremgangsmaade til saltning af koed samt anlaeg til brug ved udoevelse af fremgangsmaaden

1978
- 1978-06-15 DK DK270378A patent/DK270378A/da unknown
- 1978-06-15 DK DK270278A patent/DK270278A/da unknown
- 1978-06-19 ZA ZA00783492A patent/ZA783492B/xx unknown
- 1978-06-19 FI FI781955A patent/FI781955A7/fi not_active Application Discontinuation
- 1978-06-19 ES ES470912A patent/ES470912A1/es not_active Expired
- 1978-06-19 NZ NZ187615A patent/NZ187615A/xx unknown
- 1978-06-19 IE IE1234/78A patent/IE47200B1/en unknown
- 1978-06-19 AU AU37244/78A patent/AU3724478A/en active Pending
- 1978-06-19 FI FI781954A patent/FI64376C/fi not_active IP Right Cessation
- 1978-06-19 NO NO782128A patent/NO782128L/no unknown
- 1978-06-19 EP EP80106498A patent/EP0028017A1/de not_active Withdrawn
- 1978-06-19 EP EP78100190A patent/EP0000167A1/de not_active Withdrawn
- 1978-06-19 US US05/917,118 patent/US4278676A/en not_active Expired - Lifetime
- 1978-06-19 NO NO782127A patent/NO152049C/no unknown
- 1978-06-19 ES ES470913A patent/ES470913A1/es not_active Expired
- 1978-06-19 EP EP80106497A patent/EP0027279A1/de not_active Withdrawn
- 1978-06-19 ZA ZA00783493A patent/ZA783493B/xx unknown
- 1978-06-19 EP EP78100191A patent/EP0000338B1/de not_active Expired
- 1978-06-20 JP JP7480078A patent/JPS5436290A/ja active Pending
- 1978-06-20 CA CA305,798A patent/CA1107736A/en not_active Expired
- 1978-06-20 AU AU37298/78A patent/AU521040B2/en not_active Expired
- 1978-06-20 IT IT7868449A patent/IT7868449A0/it unknown
- 1978-06-20 AT AT0448678A patent/AT368505B/de not_active IP Right Cessation
- 1978-06-20 IT IT68450/78A patent/IT1159739B/it active
- 1978-06-20 JP JP7479978A patent/JPS5436275A/ja active Pending
1979
- 1979-09-03 NO NO792839A patent/NO792839L/no unknown
- 1979-12-17 US US06/104,080 patent/US4301287A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ATA448678A (de)	1982-02-15
CA1107736A (en)	1981-08-25
DK270278A (da)	1978-12-21
NO782127L (no)	1978-12-21
EP0000338A2 (de)	1979-01-24
FI781954A7 (fi)	1978-12-21
EP0028017A1 (de)	1981-05-06
AU3724478A (en)	1980-01-03
US4301287A (en)	1981-11-17
ZA783493B (en)	1979-06-27
JPS5436275A (en)	1979-03-16
ZA783492B (en)	1979-06-27
FI781955A7 (fi)	1978-12-21
ES470912A1 (es)	1979-02-01
FI64376C (fi)	1983-11-10
IT1159739B (it)	1987-03-04
IT7868450A0 (it)	1978-06-20
ES470913A1 (es)	1979-02-01
EP0000167A1 (de)	1979-01-10
AU3729878A (en)	1980-01-03
NO152049B (no)	1985-04-15
EP0000338B1 (de)	1981-11-25
US4278676A (en)	1981-07-14
NZ187615A (en)	1981-12-15
EP0000338A3 (en)	1979-06-27
IT7868449A0 (it)	1978-06-20
DK270378A (da)	1978-12-21
JPS5436290A (en)	1979-03-16
AU521040B2 (en)	1982-03-11
EP0027279A1 (de)	1981-04-22
FI64376B (fi)	1983-07-29
NO792839L (no)	1978-12-21
IE47200B1 (en)	1984-01-11
IE781234L (en)	1978-12-20
NO152049C (no)	1985-07-24
AT368505B (de)	1982-10-25

Publication	Publication Date	Title
NO782128L (no)	1978-12-21	Fremgangsmaate for fremstilling av fysiologisk aktive isonikotinsyrederivater
KR880000042B1 (ko)	1988-02-20	신규 유기 아마이드 화합물의 제법
JP2022174114A (ja)	2022-11-22	Ａｌｋタンパク質分解剤及びそれらの癌療法における使用
EP0595610B1 (de)	1997-05-07	Benzokondensierte Lactame
CA2807511A1 (en)	2012-02-09	Processes for preparing tubulysins
KR102842676B1 (ko)	2025-08-04	Khk 억제 효과를 갖는 화합물
SK283233B6 (sk)	2003-04-01	Deriváty benzazepinon-N-octovej kyseliny substituované kyselinou fosfónovou, ako aj spôsob ich výroby a liečivá obsahujúce tieto zlúčeniny
SE445352B (sv)	1986-06-16	Forfarande for framstellning av dipeptider, vilka inhiberar overforing av angiotensin i till angiotensin ii
JPS6058751B2 (ja)	1985-12-21	プロリン関連化合物ならびにその製法
HU223752B1 (hu)	2005-01-28	A gasztrointesztinális keringést elősegítő gyógyászati készítmény
CS621585A2 (en)	1989-08-14	Method of analynprolinone derivatives production
AU2008320718B2 (en)	2013-09-19	Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
FR2701708A1 (fr)	1994-08-26	Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament.
AU2024251729A1 (en)	2025-11-13	Synthesis of ras inhibitors
IE47481B1 (en)	1984-04-04	1-piperidinophthalazine cardiac stimulants
US4968670A (en)	1990-11-06	Pyridine-2,4- and 2,5-dicarboxylic acid derivatives, a process for their preparation, the use thereof, and medicaments based on these compounds
MXPA99003106A (es)	2004-12-02	Compuestos azaheterociclicos n-sustituidos.
JP2020500907A (ja)	2020-01-16	細胞外クエン酸の取込みの阻害剤としてのスルホンアミド
CA3155114A1 (en)	2021-05-06	Semicarbazide-sensitive amino oxidase inhibitors and use thereof
CS230562B2 (en)	1984-08-13	Production method of halogen n-/mepkaptoacyl/proline derivatives
HU198937B (en)	1989-12-28	Process for producing indolopyrazino benzodiazepine derivatives and pharmaceutical compositions comprising same
EP0145304B1 (de)	1988-04-20	Tetrahydro-beta-carbolinderivate und Verfahren zu ihrer Herstellung
IE904434A1 (en)	1991-06-19	"New thiophene derivatives, the process for the preparation thereof and the pharmaceutical compositions containing them"
CS236782B2 (en)	1985-05-15	Processing of 5 s-(2r-butyl)peptidergotalkaloid
ITMI951257A1 (it)	1996-12-14	Derivati dell'acido fosfinico ad attivita' inibitrice delle metallopeptidasi